PropertyValue
?:abstract
  • Few cases of immunoallergic tubulointerstitial nephritis associated with tyrosine kinase inhibitors have been described. We describe the first report case associated with vandetanib, a tyrosine kinase inhibitor indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (CMT) in patients with locally advanced or metastatic non-resectable disease.
is ?:annotates of
?:creator
?:doi
  • 10.1007/s10637-020-00973-8
?:doi
?:journal
  • Investigational_new_drugs
?:license
  • unk
?:pmid
?:pmid
  • 32648118.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • Medline
?:title
  • Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib.
?:type
?:year
  • 2020-07-09

Metadata

Anon_0  
expand all